Clinical Trials Sponsored by Retina Italia Onlus

Total 133 results

University of Campania "Luigi Vanvitelli"
Retina Italia Onlus

Completed

Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene (RPE65-NHS)

Leber Congenital Amaurosis 2 | Retinitis Pigmentosa 20

Italy
Fondazione ANT Italia ONLUS

Completed

Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol

Cancer | Opioid Use | Constipation Drug Induced

Italy
Fondazione Italiana Linfomi ONLUS
GRADE Onlus

Recruiting

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (FIL_PREVID)

Diffuse Large B-Cell Lymphoma | Elderly Patients

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Hepatitis C | Indolent B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Active, not recruiting

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL (FIL_KLIMT)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Active, not recruiting

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Follicular Non-Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients (GIOTTO)

Diffuse, Large B-Cell, Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (FIL-BBV)

Lymphatic Diseases

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. (FIL_BVHD01)

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM

Lymphoma, Large B-Cell, Diffuse

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients (MCL0208)

MANTLE CELL LYMPHOMA

Italy, Portugal
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

B-Cell Lymphomas

Italy, Brazil
Fondazione Italiana Linfomi ONLUS

Unknown

Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters

Lymphoblastic Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL (ANZINTER3)

Diffuse Large B Cell Lymphoma (DLBCL) | Elderly Patients (>65 Years)

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Classical Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Recruiting

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Non Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Diffuse Large B-cells Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Lymphatic Diseases

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (FIL_BRB)

Waldenstrom's Macroglobulinemia

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (R2-B)

Mantle Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Relapsed/Refractory Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT (IIL-ProHLRec)

Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients (FIL_DLCL10)

Diffuse Large B Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Aggressive Non-Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma (FIL_GAEL)

CD20 Positive Diffuse Large B-cell Lymphoma | Elderly Unfit Patients

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT (FIL_PanAL10)

Diffuse Large B-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients (FIL_GEMRO)

Peripheral T-cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (FIL_SGN01)

Primary Mediastinal Large B Cell Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Terminated

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (FIL-GALILEO)

Lymphoma, B-Cell

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (MPRvsMEL200)

Multiple Myeloma | Newly Diagnosed Patients

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Terminated

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment (PO-3887)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Recruiting

Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients (RP_MPR)

Multiple Myeloma
Fondazione EMN Italy Onlus

Completed

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients (DPd)

Multiple Myeloma | Deletion 17P Syndrome

Italy
Fondazione EMN Italy Onlus

Completed

Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) (MRD)

Multiple Myeloma

Italy
Fondazione EMN Italy Onlus

Completed

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Multiple Myeloma

Italy
Fondazione ANT Italia ONLUS
University of Bologna

Recruiting

Look of Life 2.0. Virtual Reality for Cancer Patients in Home Palliative Care (LOL2020_ANT)

Virtual Reality | Oncological Patients

Italy

3

Subscribe